Q-omics provides the consensus-scored ZNF865 profile across patient tissues and cancer cell-line models. ZNF865 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF865 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ZNF865 RNA expression shows 18,011 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where ZNF865 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF865 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF865 survival associations across molecular data types. ZNF865 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF865 RNA expression–survival associations across cancer types. High ZNF865 expression shows unfavorable associations in ACC, LIHC, LGG and CESC, but favorable associations in ESCA and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF865 RNA expression.
This table summarizes ZNF865 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF865. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF865 shows higher tumor expression in KIRC, KIRP, HNSC, LIHC, CHOL and STAD. The KIRC box plot shows higher ZNF865 RNA expression in tumor versus normal tissue (log2 FC = +0.882, t-test p < 0.001).
This table shows molecular features associated with ZNF865 in patient tissues and cancer cell lines. In patient samples, ZNF865 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF865 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
